Logo image of CRVS

CORVUS PHARMACEUTICALS INC (CRVS) Stock Fundamental Analysis

NASDAQ:CRVS - Nasdaq - US2210151005 - Common Stock - Currency: USD

4.62  +0.24 (+5.48%)

After market: 4.62 0 (0%)

Fundamental Rating

1

Overall CRVS gets a fundamental rating of 1 out of 10. We evaluated CRVS against 572 industry peers in the Biotechnology industry. CRVS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CRVS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CRVS had negative earnings in the past year.
CRVS had a negative operating cash flow in the past year.
In the past 5 years CRVS always reported negative net income.
CRVS had a negative operating cash flow in each of the past 5 years.
CRVS Yearly Net Income VS EBIT VS OCF VS FCFCRVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

CRVS has a worse Return On Assets (-96.63%) than 73.65% of its industry peers.
CRVS has a Return On Equity of -458.00%. This is in the lower half of the industry: CRVS underperforms 78.53% of its industry peers.
Industry RankSector Rank
ROA -96.63%
ROE -458%
ROIC N/A
ROA(3y)-53.13%
ROA(5y)-44.45%
ROE(3y)-62.66%
ROE(5y)-52.39%
ROIC(3y)N/A
ROIC(5y)N/A
CRVS Yearly ROA, ROE, ROICCRVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRVS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVS Yearly Profit, Operating, Gross MarginsCRVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for CRVS has been increased compared to 1 year ago.
The number of shares outstanding for CRVS has been increased compared to 5 years ago.
There is no outstanding debt for CRVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRVS Yearly Shares OutstandingCRVS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
CRVS Yearly Total Debt VS Total AssetsCRVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of -6.80, we must say that CRVS is in the distress zone and has some risk of bankruptcy.
CRVS has a worse Altman-Z score (-6.80) than 66.84% of its industry peers.
CRVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.8
ROIC/WACCN/A
WACCN/A
CRVS Yearly LT Debt VS Equity VS FCFCRVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

CRVS has a Current Ratio of 0.92. This is a bad value and indicates that CRVS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CRVS (0.92) is worse than 88.48% of its industry peers.
A Quick Ratio of 0.92 indicates that CRVS may have some problems paying its short term obligations.
CRVS's Quick ratio of 0.92 is on the low side compared to the rest of the industry. CRVS is outperformed by 87.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.92
CRVS Yearly Current Assets VS Current LiabilitesCRVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

CRVS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.63%.
EPS 1Y (TTM)-40.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CRVS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.45% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-64.6%
EPS Next 2Y6%
EPS Next 3Y-3.3%
EPS Next 5Y13.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRVS Yearly Revenue VS EstimatesCRVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
CRVS Yearly EPS VS EstimatesCRVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVS Price Earnings VS Forward Price EarningsCRVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVS Per share dataCRVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A cheap valuation may be justified as CRVS's earnings are expected to decrease with -3.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6%
EPS Next 3Y-3.3%

More info and screens

0

5. Dividend

5.1 Amount

CRVS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORVUS PHARMACEUTICALS INC

NASDAQ:CRVS (3/7/2025, 8:16:19 PM)

After market: 4.62 0 (0%)

4.62

+0.24 (+5.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)05-05 2025-05-05
Inst Owners43.45%
Inst Owner Change28.66%
Ins Owners3.91%
Ins Owner Change0%
Market Cap296.88M
Analysts87.27
Price Target15.06 (225.97%)
Short Float %11.15%
Short Ratio5.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-169.29%
Min EPS beat(2)-404.49%
Max EPS beat(2)65.9%
EPS beat(4)2
Avg EPS beat(4)-87.99%
Min EPS beat(4)-404.49%
Max EPS beat(4)65.9%
EPS beat(8)5
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-38.5%
EPS beat(16)8
Avg EPS beat(16)-28.02%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.08%
EPS NY rev (1m)0%
EPS NY rev (3m)0.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 23.92
P/tB 23.92
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -96.63%
ROE -458%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.13%
ROA(5y)-44.45%
ROE(3y)-62.66%
ROE(5y)-52.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.92
Quick Ratio 0.92
Altman-Z -6.8
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)32.55%
Cap/Depr(5y)22.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-64.6%
EPS Next 2Y6%
EPS Next 3Y-3.3%
EPS Next 5Y13.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.01%
OCF growth 3YN/A
OCF growth 5YN/A